Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.24 USD | +0.47% | +14.59% | +13.37% |
05-10 | Piper Sandler Adjusts Fate Therapeutics' Price Target to $4 From $7, Keeps Neutral Rating | MT |
05-10 | Wedbush Adjusts Fate Therapeutics' Price Target to $5 From $7, Keeps Neutral Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.37% | 483M | |
+7.52% | 113B | |
+11.38% | 106B | |
+1.48% | 22.27B | |
-12.64% | 22.22B | |
-5.10% | 19.43B | |
-37.85% | 17.87B | |
-8.58% | 17.24B | |
+7.77% | 14.29B | |
+37.41% | 12.52B |
- Stock Market
- Equities
- FATE Stock
- News Fate Therapeutics, Inc.
- Earnings Flash (FATE) FATE THERAPEUTICS Reports Q2 Revenue $0.9M, vs. Street Est of $5.7M